Brain metastases in small-cell lung cancer
Brain metastases in small-cell lung cancer
复制标题
DOI：
10.1093/oxfordjournals.annonc.a059363
复制
发表时间：
1995-11-01
影响因子：
50.5
通讯作者：
Hansen, HH
中科院分区：
文献类型：
--
作者：
Lassen, U;Kristjansen, PEG;Hansen, HH
大约10%的小细胞肺癌（SCLC）患者在诊断时存在脑转移[1]，另外40%的患者在治疗期间或治疗后出现症状性CNS受累[2]。尸检时，约50%的患者会出现脑转移[3]，两年生存期内发生脑转移的累积风险为50%-80% [2，4]。脑复发后的预后较差，中位生存期低于3个月[1，5]，而初次诊断时CNS受累的孤立预后影响极小[6]。一小部分患者将受益于放疗或化疗，并成为长期生存者，尽管他们的CNS参与[7]。
Approximately 10% of the patients with small-cell lung cancer (SCLC) present with brain metastases at the time of diagnosis [1] and another 40% develop symptomatic CNS involvement during or after treatment [2]. At autopsy approximately 50% will have brain metastases [3], and the cumulative risk of developing brain metastases at two years’ survival is 50%–80% [2, 4]. The prognosis after a cerebral relapse is poor, with a median survival below three months [1, 5], whereas the isolated prognostic impact of CNS involvement at initial diagnosis is minimal [6]. A small fraction of patients will benefit from radiotherapy or chemotherapy and become long-term survivors despite their CNS involvement [7].